14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ELVN vs MIRM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Enliven Therapeutics, Inc. (ELVN) is the stronger overall head-to-head candidate over Mirum Pharmaceuticals, Inc. (MIRM) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ELVN carries a Unified Composite Score of 36.2/100 (SELL) at $47.54 (N/M Forward P/E, 0.0% operating margin), whereas MIRM carries 38.1/100 (SELL) at $92.92 (N/M Forward P/E, -21.6% operating margin).
Composite vs. Pillar Nuance: While MIRM currently prints a higher short-term Unified Composite Score (38.1/100 SELL vs. ELVN 36.2/100 SELL), ELVN captures the overall institutional head-to-head verdict (4–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -21.6% operating margin) and revenue trajectory (+0.0% vs. +39.6% YoY).
Defensive Composite Rating Caution: Although ELVN compares more favorably head-to-head, both ELVN (36.2/100 SELL) and MIRM (38.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: ELVN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 53.2); meanwhile MIRM is in a Breakdown options structure phase (RSI 57.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ELVN vs MIRM. Trailing 12-month operating profitability (ELVN 0.0% vs MIRM -21.6%) and valuation multiples (ELVN N/M vs MIRM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $6.1B market capitalization and -21.6% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ELVN vs MIRM Key Questions & Quantitative Answers
As of Nov 16, 2026, Enliven Therapeutics, Inc. (ELVN) is the stronger overall head-to-head candidate over Mirum Pharmaceuticals, Inc. (MIRM) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ELVN carries a Unified Composite Score of 36.2/100 (SELL) at $47.54 (N/M Forward P/E, 0.0% operating margin), whereas MIRM carries 38.1/100 (SELL) at $92.92 (N/M Forward P/E, -21.6% operating margin). Composite vs. Pillar Nuance: While MIRM currently prints a higher short-term Unified Composite Score (38.1/100 SELL vs. ELVN 36.2/100 SELL), ELVN captures the overall institutional head-to-head verdict (4–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -21.6% operating margin) and revenue trajectory (+0.0% vs. +39.6% YoY). Defensive Composite Rating Caution: Although ELVN compares more favorably head-to-head, both ELVN (36.2/100 SELL) and MIRM (38.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: ELVN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 53.2); meanwhile MIRM is in a Breakdown options structure phase (RSI 57.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MIRM leads the Growth & Scale pillar: ELVN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MIRM at +39.6% YoY revenue growth and +0.0% YoY earnings growth on $671M TTM revenue (81.7% gross margin, -21.6% operating margin). On trailing 12-month operating scale, ELVN generates N/A in USD-normalized revenue versus $671M for MIRM. In operating R&D and SG&A reinvestment, ELVN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MIRM.
MIRM screens cheaper on headline valuation multiples. ELVN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas MIRM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.8x EV/Revenue (-46.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ELVN (-16.8% ROE) versus MIRM (-760.0% ROE) capital efficiency.
In options market volatility and institutional positioning, ELVN carries 46.9% implied volatility (5th %ile, Compressed (<25th %ile)), a 1.67x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.96β · 60% Vol realized risk). By comparison, MIRM carries 72.6% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.02β · 49% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.